Clinical Trial Update: Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the combination of docetaxel and samarium-153-EDTMP in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Quadramet (samarium-153 lexidronam pentasodium)
• Taxotere (docetaxel)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED